Fundamental Analysis

ASTRAZENECA PHARMA INDIA

Ticker : 506820
BUY: Rs 3537.75
Target: Rs 3900

AstraZeneca Pharma India Limited is a global biopharmaceutical company engaged in the discovery, development, and commercialisation of medicines for core areas of healthcare. On a standalone quarterly front, the net sales fell by 5.37 per cent to Rs 193.58 crore in Q1FY21 from Rs 204.56 crore in Q1FY20. Operating profit was reported at Rs 31.22 crore in Q1FY21, declining by 19.02 per cent from Rs 38.55 crore in the same quarter of the previous fiscal year. The net profit of the company contracted by 13.39 per cent to Rs 18.63 crore in Q1FY21 from Rs 21.52 crore in Q1FY20. In August 2020, the company received import and market permission from Drugs Controller General of India (DCGI) for Olaparib film-coated tablets 100 mg and 150 mg, paving the way for its launch in India. New product launches along with expected growth in the Indian pharmaceutical market are positives that should spur recovery for AstraZeneca Pharma. We recommend a BUY.